Arrowhead, Janssen pen deal worth up to $3.7bn
In a deal potentially worth $3.7bn, Arrowhead Pharmaceuticals Inc. licensed Janssen Pharmaceuticals Inc. exclusive worldwide rights to develop and commercialize its ARO-HBV program. In addition, Janssen has the exclusive option to select up to three targets outside of Arrowhead’s current pipeline.
- Drug Delivery
- Antisense, Oligonucleotides
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.